Purpose of review Lungs are extremely susceptible to injury, and despite advances in surgical management and immunosuppression, outcomes for lung transplantation are the worst of any solid organ transplant. The success of lung transplantation is limited by high rates of primary graft dysfunction because of ischemiareperfusion injury characterized by robust inflammation, alveolar damage, and vascular permeability. This review will summarize major mechanisms of lung ischemia-reperfusion injury with a focus on the most recent findings in this area.
INTRODUCTION
Inflammation typically occurs in response to infection, which is critical for pathogen eradication and tissue repair. However, 'sterile inflammation' can occur during noninfectious conditions, including trauma, chemically induced injury, or ischemia [1] . In these cases, activation of the innate immune system promotes inflammation. In lung transplantation, organ ischemia and subsequent reperfusion is unavoidable and commonly leads to acute, sterile inflammation after transplant called ischemiareperfusion injury. This is a major clinical issue because severe ischemia-reperfusion injury leads to primary graft dysfunction (PGD), which is the major source of both short-and long-term morbidity and mortality after lung transplantation [2,3 && ]. Currently, there are no therapeutic agents clinically utilized to specifically prevent ischemia-reperfusion injury, and treatment strategies are limited to supportive care. The annual number of lung transplantations keeps growing, and major research efforts have been aimed toward: better preserving donor lungs, expanding the donor lung pool, reconditioning of marginal donor lungs via ex-vivo lung perfusion, and developing methods to prevent or treat ischemia-reperfusion injury. Thus understanding the cellular and molecular mechanisms of lung ischemia-reperfusion injury is paramount for the translation of these research efforts into clinical application. This article will provide a review of general mechanisms of lung ischemiareperfusion injury with a focus on the most recent findings in this area. The complex nature of lung ischemia-reperfusion injury is illustrated in Fig. 1 , which highlights many of the inflammatory pathways discussed in this review that contribute to lung ischemia-reperfusion injury.
ISCHEMIA-REPERFUSION INJURY AND CLINICAL IMPACT
Ischemia (cessation of blood flow) and severe hypoxia of the explanted, donor lung is unavoidable before transplantation, and the use of cold preservation solutions are used to minimize ischemic injury. Because PGD is a complication that leads to severe early and long-term consequences for lung transplant recipients, transplant teams tend to be very conservative in the selection of donor lungs. PGD, largely because of ischemia-reperfusion injury, is associated with significant early and late mortality after transplant, and severe (Grade 3) PGD has an incidence of approximately 30% within 72 h of transplant [3 && ]. PGD is also a risk factor for late graft rejection (bronchiolitis obliterans), the major cause of mortality in recipients beyond 1 year of transplant [4, 5] . Clearly, methods for prevention of ischemia-reperfusion injury are deeply needed to improve both short-and long-term outcomes after lung transplantation.
ISCHEMIA-REPERFUSION INJURY ENTAILS ROBUST OXIDATIVE STRESS RESPONSES
Although reperfusion of the ischemic lung is mandatory to prevent irreversible ischemic damage, it also paradoxically promotes further damage and dysfunction; so-called ischemia-reperfusion injury. Ischemia-reperfusion injury is a rapid and complex inflammatory response that entails endothelial and epithelial injury/dysfunction, release of cytokines and damage-associated molecular patterns (DAMPs), and vigorous innate immune responses, including activation of alveolar macrophages, invariant natural killer T (iNKT) cells, and neutrophils. Most of these responses are initiated by rapid and robust generation of reactive oxygen species (ROS) that leads to cell/tissue injury, activation of multiple cell types, lipid membrane peroxidation, and secretion of inflammatory cytokines and DAMPs [6] .
A recent study by Gielis et al. [7 & ] used electron spin resonance to quantify free radical formation after lung ischemia-reperfusion in mice and revealed a major radical 'burst' peaking 1 h after reperfusion followed by a swift stabilization of the oxidative environment. This study also demonstrated acute oxidative stress in peripheral blood during ischemia and reperfusion. A study by Chatterjee et al. ] provided evidence that the cessation of blood flow during lung ischemia is 'sensed' by the endothelium via a mechanosignaling cascade that depolarizes endothelial cell membranes and activates the phagocytic isoform of NADPH oxidase (NOX2) to generate ROS and nitric oxide, ultimately leading to oxidative injury, and activation of signaling pathways that drive inflammation and cell death. This likely contributes to the development of life-threatening pulmonary edema in recipients with PGD. A recent analysis of patients from the Lung Transplant Outcomes Group cohort aimed to identify genetic variation in oxidative stress genes associated with PGD [9 && ]. This study identified several genes associated with PGD and concluded that donor-recipient interactions between functional single nucleotide polymorphisms in the NOX3 and nuclear factor, erythroid 2-like 2 (NFE2L2) genes may be highly relevant. The effects of these interactions highlight the importance of oxidative stress detoxifiers (encoded by NFE2L2) in lung recipients and ROS generators (encoded by NOX3) in lung donors. Oxidative stress after ischemia-reperfusion causes DNA breaks, which in turn activates DNA nick sensor enzyme poly(ADP-ribose) polymerase (PARP) that plays an important role in DNA repair. Using a rat lung ischemia-reperfusion model, Hatachi et al. [10 & ] demonstrated a role for PARP in ischemia-reperfusion injury by showing that PARP inhibition attenuates inflammation and tissue damage caused by ischemia-reperfusion.
Our laboratory has described a pivotal role for iNKT cells in the initiation of lung ischemiareperfusion injury via an IL-17A-dependent mechanism [11] , and we have shown that NOX2 in bone marrow-derived cells mediates lung ischemia-
KEY POINTS
Ischemia-reperfusion injury after lung transplantation is a real clinical issue because it often leads to PGD, the major cause of morbidity, and mortality after transplant.
Ischemia-reperfusion injury entails complex inflammatory communication between donor lung cells and infiltrating immune cells from the recipient, ultimately leading to breakdown of endothelial and epithelial barriers to result in life-threatening edema and organ dysfunction.
The robust oxidative stress that rapidly occurs upon reperfusion is a major initiating factor of ischemiareperfusion injury, and recent studies have provided further understanding of the cells and pathways involved to help develop more effective targeted therapies.
Future studies should focus more on translating experimental results to clinical trials with the idea that the most effective therapies will likely target multiple, intracellular communications, and intercellular pathways that lead to tissue injury and organ dysfunction.
reperfusion injury [12] . In a recent follow-up study, we demonstrated that activation of NOX2 in iNKT cells provides the mechanism for IL-17A production after ischemia-reperfusion leading to inflammation, neutrophil infiltration, and pulmonary injury [13 & ].
We have previously demonstrated the potent ability of adenosine A2A receptor (A2AR) agonists to prevent ischemia-reperfusion injury [14] , and our recent study also revealed that a primary mechanism for A2AR agonist-mediated protection entails inhibition of NOX2 in iNKT cells [13 & ]. Thus agonism of A2ARs on iNKT cells may be a novel therapeutic strategy to prevent PGD after lung transplantation.
INNATE IMMUNE RESPONSES
Ischemia reperfusion after lung transplant rapidly activates the innate immune system to promote inflammation and injury [15] . Receptors that mediate the response to microbial infection, notably Toll-like receptors (TLRs), have also been implicated in lung ischemia-reperfusion injury. TLR4, the mammalian lipopolysaccharide (LPS) receptor, has been shown to respond to endogenous molecules during sterile inflammation such as after ischemiareperfusion [1] . Such endogenous molecules, termed DAMPs, include high-mobility group box 1 (HMGB1), fibronectin, oxidized phospholipids, , to secrete neutrophil chemokines [chemokine C-X-C motif ligand 1 (CXCL1) and CXCL2)] via DAP12, proinflammatory cytokines (e.g., TNFa), and high-mobility group box 1 (HMGB1). HMGB1 binds to receptor for advanced glycation end products (RAGE) to induce IL-17 secretion by invariant natural killer T cells (iNKT). TNFa induces the production of IL-8, another potent chemokine, by alveolar type 2 epithelial cells (AT2); a process augmented by IL-17. Elevated chemokine levels and adhesion molecule expression on ECs and neutrophils (PMN) leads to binding and infiltration of neutrophils, which can release cytokines, ROS and form neutrophil extracellular traps (NETs). AT1, alveolar type 1 epithelial cell.
and heat shock proteins among others. TLR4 has been implicated as a key modulator of lung ischemia-reperfusion injury [16] , and Merry et al. [17] recently utilized small interfering RNA knockdown of TLR4 in rats to demonstrate that TLR4 activation, largely in alveolar macrophages, is important for the initiation of lung ischemia-reperfusion injury. Phelan et al. [18] used an in-vitro model to confirm that TLR4 modulates cytokine responses of alveolar macrophages after acute hypoxia-reoxygenation. A third study by this group demonstrated that TNFa and IL-1b, secreted by alveolar macrophages, prime, and amplify the response of endothelial and epithelial cells through parallel pathways after exposure to hypoxia-reoxygenation [19] . Finally, although ischemia-reperfusion injury is considered a sterile inflammatory condition, an interesting study by Prakash et al. [20] suggests that the inflammatory response induced by lung ischemiareperfusion is transient and strongly influenced by intestinal microbiota. Here, treatment of mice with intestinally localized antibiotics was associated with attenuation of lung inflammatory markers, cell infiltration and edema in the lung after ischemia-reperfusion. These authors speculate that the commensal microbiota may provide an initial 'priming' signal that signals alveolar macrophages to generate IL-1b via inflammasome activation. The activation and infiltration of innate immune cells, especially neutrophils as end-effectors of tissue injury, has been well documented after lung ischemia-reperfusion [11, [21] [22] [23] . Infiltration of circulating host neutrophils into the graft is a key aspect of ischemia-reperfusion injury largely driven by potent chemokines, (e.g., IL-8 and CXCL2) produced by donor lung cells such as epithelium, endothelium, or macrophages [24] . Several recent studies provide new insight into mechanisms of neutrophil-mediated ischemiareperfusion injury. DAP12 is a membrane-associated protein expressed in myeloid cells that can augment or dampen innate inflammatory responses. Using DAP12 À/À mice as donors or recipients, Spahn and colleagues [25 && ] showed that donor deficiency in DAP12 attenuates ischemia-reperfusion injury in a murine lung transplantation model. Further analysis demonstrated that DAP12 mediates the production of neutrophil chemoattractants, specifically CXCL2, and also revealed a trans-endothelial migration defect in DAP12 À/À lungs that could be rescued by local administration of CXCL2. Thus DAP12 expression in macrophages mediates lung ischemia-reperfusion injury by promoting neutrophil trafficking. Another study by Sayah et al. [26 && ] showed that neutrophil extracellular traps (NETs) are induced after lung ischemia reperfusion in two murine models and in human lung transplants. Considered by many to be an effector function of neutrophils, NETs are comprised of extracellular elaborations of DNA complexed with histones and neutrophil granular proteins and generated by a regulated cell death program called 'NETosis'. In this study, NET formation was attenuated by DNase I treatment that also correlated with reduced lung ischemia-reperfusion injury, and NETs were found to be more abundant in lungs of patients with PGD. Thus this study provided the first evidence of a pathogenic role for NETs in solid organ transplantation.
Early growth response-1 (Egr-1) is a zinc finger transcription factor that regulates the expression of multiple target genes, including those involved in inflammatory cytokine and coagulant pathways. Using wild-type or Egr-1 À/À mice, Yamamoto et al.
[27] demonstrated that lung function after transplantation was most improved when donor and recipient animals were Egr-1 deficient, and graft function was intermittently improved when either the donor or recipient animal was Egr-1 deficient. Graft function correlated inversely with neutrophil infiltration, and Egr-1 expression was detected in neutrophil cytoplasm. These results suggest that graft Egr-1 has a greater contribution to lung ischemia-reperfusion injury through the regulation of neutrophil infiltration.
Mast cells can be important for initiation of immune responses via rapid generation of proor anti-inflammatory mediators, but their role in lung ischemia-reperfusion injury has remained unknown. Although mast cells can act as key regulators of tolerance depending on the nature of the mast cell subsets, their phenotype, and environment, only a few studies have addressed a potential role for mast cells in lung ischemia-reperfusion injury. Greenland and colleagues [28] recently reported that lung ischemia-reperfusion injury (extravascular lung water and endothelial permeability) in mast cell-deficient animals was similar to wild-type mice and concluded that mast cells are not necessary for the development of PGD.
ENDOTHELIAL BARRIER FUNCTION
Endothelial cell dysfunction and disruption of the endothelial barrier are hallmarks of lung ischemia-reperfusion injury and contribute greatly to PGD. As discussed above, depolarization of endothelial cell membranes induces ROS production, and subsequent inflammation and leukocyte extravasation [8 && ]. Integrins are surface receptors important in maintenance of the cell barrier, and integrin avb5 has been shown to mediate vascular leak [29] . Mallavia et al. [30 & ] recently used a murine lung transplant model to show that treatment of donor lungs with avb5 blocking antibody provided robust protection from ischemia-reperfusion injury, decreased vascular leak and neutrophil infiltration, and improved oxygenation following reperfusion. Although the mechanisms for avb5mediated endothelial permeability remain unclear, these results have translational potential and may support the application of avb5 blocking strategies during ex-vivo lung perfusion to prevent edema.
Endothelial barrier integrity as well as immune cell trafficking and function are several aspects attributed to the actions of sphingosine 1-phospate (S1P), a biologically active lipid mediator that signals via a family of five G protein-coupled receptors (S1PR1-5) [31]. Our group recently measured lung ischemia-reperfusion injury in mice treated with either FTY720 (a nonselective S1P receptor agonist) or VPC01091 (a selective S1PR1 agonist and S1PR3 antagonist) [32 & ]. We demonstrated that VPC01091 was equally protective as FTY720 against lung injury and vascular permeability after ischemia reperfusion, suggesting that S1P-mediated protective mechanisms are primarily dependent on S1PR1 agonism. Use of selective S1PR1 agonists like VPC01091 may be a more effective approach to S1P receptor-targeted therapy because it avoids potential deleterious effects of S1PR3-mediated profibrotic processes after lung injury.
Mammalian cells have an oxygen-sensing capacity as a protective response to hypoxic or ischemic injury, and hypoxia-inducible factors (HIFs) are well described 'master regulators' of these cellular responses by regulating a multitude of genes affecting metabolism and inflammation after transplantation [33] . Zhao et al. [34] used a rat model to demonstrate that HIF-1a contributes to pulmonary vascular dysfunction after lung ischemia-reperfusion and that a HIF-1a stabilizer, dimethyloxaloylglycine (DMOG), provides significant protection. A more recent study demonstrated the importance of aquaporin 1 (AQP1), a water channel protein expressed widely in vascular endothelium, in the resolution of lung ischemia-reperfusion injury through the stabilization of HIF-2a protein [35 & ]. Here, AQP1 À/À mice had enhanced leukocyte infiltration and microvascular permeability as well as repressed HIF-2a stability, and HIF-2a overexpression restored the expression of angiogenic factors in pulmonary microvascular endothelial cells exposed to hypoxia-reoxygenation. These results suggest that AQP1 may participate in the resolution of lung ischemia-reperfusion injury via mediating HIF-2a stability and promoting angiogenesis.
STRATEGIES TO LIMIT ISCHEMIA-REPERFUSION INJURY
Many strategies have been shown to limit ischemiareperfusion injury in experimental settings, which often reveal mechanistic insight. Most of these studies have been performed in animal models in which treatment was given either to the recipient or to the donor before lung reperfusion. Recent studies have identified a variety of strategies including: antioxidant strategies using free radical scavengers or inhibitors of oxidant-producing enzymes (e.g., methylene blue [36] or N-acetylcysteine [37] ); antiinflammatory strategies using inhibitors of proinflammatory transcription factors (e.g., inhibitor of Egr-1 [27]) or inflammatory mediators (e.g., a1-antitrypsin [38 & ], anticytokine [11] , or anti-HMGB1 [39] agents); ventilation with gaseous molecules (e.g., carbon monoxide [40] ) or inhaled anesthetic sevoflurane [41] that display anti-inflammatory properties; growth factors (e.g., keratinocyte growth factor-2 [42] ); dietary supplements such as creatine [43] ; and cell-based therapies such as application of mesenchymal stem cells [44, 45] . In addition, a recent study by Hashimoto et al. [46] showed that treatment with diannexin (a homodimer of annexin V, an anionic phospholipid-binding protein with potent anticoagulant activity) significantly reduced ischemia-reperfusion injury in a lung transplant model by reducing cell death and tissue inflammation.
Extracellular ATP (eATP), a DAMP molecule, has been shown to accumulate in rat lung isografts injured by prolonged cold preservation, both of which were attenuated by apyrase treatment [47] . This same group more recently confirmed the role of eATP in lung ischemia-reperfusion injury by demonstrating that apyrase treatment provided protection in a canine model of lung ischemia-reperfusion injury [48 && ]. Of particular interest, this study also demonstrated that human lung recipients with moderate-to-severe PGD had significantly higher eATP levels, and thus strategies aimed toward reducing eATP levels may be an area worth exploring to prevent PGD in transplant patients.
Pulmonary epithelial cells were the focus in a recent study by Kim et al. [49 & ] that utilized an invitro model that simulates lung preservation and transplantation. They found that protein kinase C (PKCd) was activated in epithelial cells during cold ischemia and that treatment with dV1-1, a peptide PKCd inhibitor, reduced translocation of PKCd, and p53 to the mitochondria and also attenuated ischemia-reperfusion injury after lung transplantation in rats. Thus inhibition of PKCd may be an effective strategy to prevent injury and necrosis after ischemia-reperfusion.
Several studies have explored the role of autophagy in lung ischemia-reperfusion injury. Autophagy is a homeostatic cellular process that degrades cytoplasmic components within the lysosome and is an important cytoprotective response to pathologic stresses such as after ischemia [50] . Results from a study by Zhang et al. suggested that autophagy plays a protective role in lung ischemia-reperfusion injury via extracellular signal-regulated kinase1/2 signaling and that this effect may be enhanced by facilitating autophagy via rapamycin treatment [51 & ]. This same group attributed enhanced autophagy levels as a mechanism for the attenuation of lung ischemia-reperfusion injury by administration of mesenchymal stem cells [52 & ]. However, some controversy exists as to the precise role of autophagy as an earlier study concluded that inhibition of autophagy by 3-methyladenine ameliorates lung ischemia-reperfusion injury [53].
CONCLUSION
Lung ischemia-reperfusion injury is a complex, 'sterile' inflammatory condition involving rapid oxidative stress and subsequent responses by all cells globally within the lung, ultimately leading to breakdown of the endothelial and epithelial barriers resulting in life-threatening edema and defective gas exchange. Some of the major players are innate immune cells that are rapidly activated upon reperfusion and that induce direct tissue injury or augment inflammation via production of proinflammatory cytokines and DAMPs. Although many experimental studies have described various methods to prevent or dampen ischemia-reperfusion injury, these have not yet been translated into clinical use. Thus the thrust of future research should aim to better understand mechanisms of lung ischemia-reperfusion injury to identify more effective therapeutic targets and also aim to push the most promising therapies toward clinical trials. Because ischemia-reperfusion injury involves complex intra and intercellular communications in the lung, therapies that simultaneously target multiple pathways and cell types will likely be required to most effectively treat or prevent PGD. In addition to revealing a major radical 'burst' peaking 1 h after reperfusion in murine lungs, this study also demonstrated acute oxidative stress in peripheral blood during ischemia and reperfusion.
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